Novelstem International CorpOOTC NSTM Stock Report

NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The Company’s NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. The Company’s diagnostic technology predicts patients’ anti-cancer drug resistance, which allows targeted cancer treatments and the potential to reduce resistance to chemotherapy. The Company’s technology is also being used for genetic research related to other medical therapies.